Neumora Therapeutics (NMRA) Enterprise Value (2022 - 2026)
Neumora Therapeutics' quarterly Enterprise Value came in at -$147.1 million in Q1 2026, down 14.83% year-on-year from -$172.7 million in Q1 2025, and up 19.43% quarter-over-quarter from -$182.5 million in Q4 2025.
Neumora Therapeutics has reported Enterprise Value for 5 years, with the latest figure at -$147.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 14.83% year-over-year to -$147.1 million; the trailing twelve-month figure through Mar 2026 stood at -$147.1 million (down 14.83% YoY), and the FY2025 full-year result was -$182.5 million, up 40.66% from the prior year.
- Enterprise Value for Q1 2026 stood at -$147.1 million, up from -$182.5 million in the prior quarter.
- The five-year high for Enterprise Value was -$124.5 million in Q2 2025, with the low at -$509.6 million in Q3 2023.
- Average Enterprise Value over 5 years is -$272.9 million, with a median of -$252.5 million recorded in 2022.
- Year-over-year, Enterprise Value sank 101.8% in 2023 and soared 69.7% in 2025.
- Tracing NMRA's Enterprise Value over 5 years: stood at -$371.9 million in 2022, then declined by 22.08% to -$454.0 million in 2023, then jumped by 32.25% to -$307.6 million in 2024, then soared by 40.66% to -$182.5 million in 2025, then rose by 19.43% to -$147.1 million in 2026.
- The last three Enterprise Value figures came in at -$147.1 million (Q1 2026), -$182.5 million (Q4 2025), and -$129.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -147.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.07 Mn |
| Dec 31, 2025 | -182.53 Mn |
| Sep 30, 2025 | -129.07 Mn |
| Jun 30, 2025 | -124.52 Mn |
| Mar 31, 2025 | -128.07 Mn |
| Dec 31, 2024 | -307.58 Mn |
| Sep 30, 2024 | -276.93 Mn |
| Jun 30, 2024 | -371.64 Mn |
| Mar 31, 2024 | -422.72 Mn |
| Dec 31, 2023 | -453.98 Mn |
| Sep 30, 2023 | -509.57 Mn |
| Jun 30, 2023 | -204.22 Mn |
| Mar 31, 2023 | -210.87 Mn |
| Dec 31, 2022 | -371.88 Mn |
| Sep 30, 2022 | -252.51 Mn |